Outcomes of Anti-HIV Therapy During Early HIV Infection

NCT ID: NCT00001093

Last Updated: 2012-10-29

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 48 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 1999-10-31
• Study Completion Date: 2007-06-30

Brief Summary

The purpose of this study is to find out if it is effective to give aggressive anti-HIV therapy to patients who have been infected recently with HIV.

Many doctors recommend that patients who have recently been infected with HIV begin anti-HIV treatment as soon as possible. However, early HIV infection is not yet completely understood, so it is not known if this is the best approach. This study will look at the effects of beginning anti-HIV treatment during early HIV infection.

Detailed Description

Although many researchers have recommended initiation of aggressive antiretroviral therapy as soon as possible after HIV infection occurs, the tolerability and efficacy of this approach has not been systemically evaluated. Many features of primary HIV pathogenesis are incompletely understood. A more complete understanding of immune dynamics and viral pathogenesis during primary HIV infection is critical to determine optimal treatment intervention strategies. This study will evaluate the outcomes of potent antiretroviral therapy initiated at different stages of primary HIV infection.

Thirty-six of the study patients are coenrolled to ACTG 371 or another treatment protocol. All study drug treatment and toxicity management is performed according to guidelines in these treatment protocols. An untreated cohort of 12 patients is also followed on this study. Patients are stratified at enrollment according to their stage of acute or early HIV infection. Patients are evaluated for virologic, immunologic, and clinical parameters for 96 weeks. In addition, novel studies of source partner identification are proposed. An effort is made to determine the most likely source partner(s) for each study patient on the basis of patient recall of possible exposures. A separate study protocol will evaluate the source partner.

Conditions

HIV Infections

Keywords

Immunity, Cellular; Sexual Partners; Treatment Outcome; Anti-HIV Agents; Viral Load; Acute Infection

Eligibility Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are at least 13 years old.
• Have acute or early HIV infection. The stage of HIV infection will depend on the results from certain lab tests.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Are pregnant or breast-feeding.

• Minimum Eligible Age: 13 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Principal Investigators

Susan Little

Role: PRINCIPAL_INVESTIGATOR

James Kahn

Role: PRINCIPAL_INVESTIGATOR

Eric Daar

Role: PRINCIPAL_INVESTIGATOR

Locations

Cedars Sinai Med Ctr

Los Angeles, California, United States

UCSD

San Diego, California, United States

San Francisco Gen Hosp / UCSF AIDS Program

San Francisco, California, United States

Countries

United States

Other Identifiers

AEHIV 005

Identifier Type: -

Identifier Source: secondary_id

AIEDRP AI-05-005

Identifier Type: -

Identifier Source: secondary_id

AI-05-005

Identifier Type: -

Identifier Source: org_study_id